Accel­er­ate devel­op­ment of GMP-grade pro­duc­tion enzymes essen­tial for man­u­fac­tur­ing mRNA-based biopharmaceuticals
SEOUL, Korea and LANGENFELD, Ger­many, Octo­ber 13, 2021 / B3C newswire 

Today, Cel­lumed Co. Ltd., list­ed stock mar­ket com­pa­ny and Ger­many based ARTES Biotech­nol­o­gy GmbH announce the exe­cu­tion of a Devel­op­ment and License Agree­ment aim­ing at the gen­er­a­tion of micro­bial pro­duc­tion cell lines, process­es and doc­u­men­ta­tion for the cGMP man­u­fac­tur­ing of two enzymes required in the man­u­fac­tur­ing process of mRNA vaccines.
Under this agree­ment, ARTES shall be respon­si­ble for the devel­op­ment of high yield micro­bial cell lines express­ing two recom­bi­nant enzymes. Fur­ther steps at ARTES will include the devel­op­ment of up- and down­stream process­es as well as of the ana­lyt­i­cal assays to char­ac­ter­ize the two prod­ucts. Results will be trans­ferred by ARTES to its Ger­man CMO part­ner Richter-Helm Bio­Log­ics GmbH & Co. KG for sub­se­quent cGMP pro­duc­tion. The project man­age­ment will be sup­port­ed by ARTES´ Kore­an rep­re­sen­ta­tive Qual­i­ty by Design, Inc.

Cel­lumed pre­dicts that the mRNA plat­form will grad­u­al­ly expand prod­uct devel­op­ment in the future as a base tech­nol­o­gy with high poten­tial for devel­op­ing oth­er vac­cines and ther­a­peu­tics even after COVID-19 sub­sides. There­fore, Cel­lumed will real­ize tech­no­log­i­cal inde­pen­dence of mate­ri­als through the local­iza­tion of pro­duc­tion enzymes, which are key raw mate­ri­als for mRNA vac­cines. In addi­tion, it is plan­ning to sup­ply pro­duc­tion enzymes in Korea first, and is also plan­ning to grad­u­al­ly advance into the glob­al market.

State­ment of Dr. Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES Biotech­nol­o­gy: “We are very proud being cho­sen by Cel­lumed for this impor­tant task of sup­port­ing the estab­lish­ment of most up-to-date mRNA tech­nol­o­gy in South-Korea. We will con­tribute our long term expe­ri­ence in recom­bi­nant biotech­nol­o­gy and will give all our out­stand­ing exper­tise and know-how in this col­lab­o­ra­tion. We are look­ing for­ward to build­ing a strong and long last­ing rela­tion with Cellumed.”